On July 22, Argenx SE rose 3.25% in regular trading, trading at $873.67/share, with turnover of $186 million. The move comes one day before the company is scheduled to release its Q2 earnings report on July 23 pre-market.

Market consensus expects Q2 revenue of $1.443 billion, representing 53.14% year-over-year growth, with adjusted EPS forecast at $6.15, up 81.68% year-over-year. Multiple institutions have issued buy ratings, with BNP Paribas initiating coverage at Outperform with a $1,219 price target. The bullish sentiment is underpinned by strong fundamentals: core product Vyvgart recently secured FDA approval expanding its label to all serotypes of generalized myasthenia gravis, which eliminates a key rate-limiting step in prescribing. Additionally, Vyvgart's CIDP patient share is expected to rise from 18% to 23%, supporting continued commercial momentum heading into the earnings print.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)